SCORE2 Report 2: Study Design and Baseline Characteristics.
Feb 01 2017
PubMed ID: 27863843 Author(s): Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group. SCORE2 report 2: study design and baseline characteristics. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub…
Read MoreSCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.
Oct 01 2016
PubMed ID: 27450625 Author(s): Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M; SCORE2 Investigator Group. SCORE2 report 1: techniques to optimize recruitment in Phase III clinical trials of patients with central…
Read MoreReply.
Feb 01 2016
PubMed ID: 26696314 Author(s): Eadie JA, Ip MS. Reply. Retina. 2016 Feb;36(2):e10-2. doi: 10.1097/IAE.0000000000000918. PMID 26696314 Journal: Retina (Philadelphia, Pa.), Volume 36, Issue 2, Feb 2016
Read MoreIncidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.
Sep 01 2015
PubMed ID: 26086920 Author(s): Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for…
Read MoreReply: To PMID 24999721.
Aug 01 2015
PubMed ID: 26166802 Author(s): Eadie JA, Ip MS. Reply: To PMID 24999721. Retina. 2015 Aug;35(8):e54-5. doi: 10.1097/IAE.0000000000000682. PMID 26166802 Journal: Retina (Philadelphia, Pa.), Volume 35, Issue 8, Aug 2015
Read MoreEffects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Apr 01 2015
PubMed ID: 25601535 Author(s): Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology. 2015 Apr;122(4):779-86.…
Read MoreLong-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Feb 01 2015
PubMed ID: 25439595 Author(s): Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015 Feb;122(2):367-74. doi: 10.1016/j.ophtha.2014.08.048. Epub…
Read MoreResponse to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Dec 01 2014
PubMed ID: 24999721 Author(s): Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina.…
Read MoreLocalized retinal manifestations of paraneoplastic autoimmune retinopathy.
Oct 01 2014
PubMed ID: 25372537 Author(s): Eadie JA, Ip MS, Ver Hoeve JN. Localized retinal manifestations of paraneoplastic autoimmune retinopathy. Retin Cases Brief Rep. 2014 Fall;8(4):318-21. doi: 10.1097/ICB.0000000000000054. PMID 25372537 Journal: Retinal Cases & Brief Reports, Volume…
Read More